论文部分内容阅读
2006年1月,美国食品及药物管理局(FDA)批准了第一个可吸人性的胰岛素制剂用于治疗1型和2型糖尿病。该胰岛素制剂由辉瑞制药公司生产,是一种干粉状的人常规胰岛素,能通过一种可以手握的装置形成气雾剂,在吸气时吸入。它有1 mg 和3 mg 两种箔包装,分别释放3单位和9单位胰岛素。因为皮下注射1单位胰岛素大约相当于30 λμg胰岛素,所以依据重量,吸入胰岛素的活性只是注射胰岛素的10％。与皮下注射胰岛素相比,这一“低效性”带来了
In January 2006, the U.S. Food and Drug Administration (FDA) approved the first inhalable insulin formulation to treat Type 1 and Type 2 diabetes. Manufactured by Pfizer, the insulin preparation is a dry, powdery, conventional insulin that can be inhaled during inhalation through a hand-held device to form an aerosol. It is available in 1 and 3 mg foil packages, releasing 3 units and 9 units of insulin, respectively. Because subcutaneous injection of 1 unit of insulin corresponds to about 30 μg of insulin, the insulin-in-activity is only 10% of insulin injected by weight. This “inefficiency” comes in comparison with subcutaneous insulin injections